Previous month:
October 2007
Next month:
December 2007

Going to Great Lengths: Eyelash Treatment Seized by FDA

A well-documented side-effect of anti-glaucoma medications (like Lumigan(R), Xalatan(R) and Travatan(R)) is increased eyelash length, density and pigmentation.    These glaucoma drugs all contain active ingredients that fall into the category of Prostaglandin Analogues (or Analogs).     Bimatoprost, the active ingredient in Lumigan(R), appears to be one of the more potent stimulators of eyelash growth.     Well before the popular formulations of Jan Marini Age Intervention Eyelash, Revitalash and MD Lash Factor were available, doctors were able to write 'off-label' prescriptions for the topical use of medications, like Lumigan(R) for example, for their cosmetic patients who had weak lashes.   

In September 2006, the FDA embargoed Jan Marini's Age Intervention Eyelash (JMAIE) product due to problems with 'labelling.'   Reformulating the product and packaging, the JMAIE was re-released and distributed starting around February of 2007.     It appears that the initial product contained bimatoprost, but the new formulation has a different, perhaps new, prostaglandin analogue. 

While the JMAIE was off the market, Revitalash appeared on the scene with an eyelash conditioner formulation which received rave reviews from patients.     According to Athena Cosmetics (makers of Revitalash), it appears that Revitalash does contain bimatoprost--but at a much smaller concentration than the drug Lumigan(R).   At this time, Revitalash voluntarily no longer distributing their product, but promises to re-release a new formulation shortly. 

MD Lash Factor, made by Procyte/Photomedix, also contains a prostaglandin analogue--not bimatoprost, but a 'novel' compound.